OVID PRESS-RELEASE SEC Filing Analysis

Latest settled — T+5d

OVID ▼ -16.03% at T+5d

NEUTRAL call ✗ call lost -16.03% · α vs SPY -16.11% · entry $2.87 → $2.41

Next anchor: T+20d due 5d ago

Last close $2.30 (close Jun 12) · -19.86% from $2.87 entry

Entry anchored
May 11, 03:59 PM ET
via Databento tick

T+1d

-2.44%

call -2.44% · α -3.01%

$2.80

settled 5w ago

T+5d

-16.03%

call -16.03% · α -16.11%

$2.41

settled 27d ago

T+20d

—

call — · α —

—

due 5d ago

T+60d

—

call — · α —

—

in 7w

Price Chart

Loading chart...

Executive Summary

Ovid Therapeutics reported Q1 2026 financial results featuring a net loss of $17.0M (-$0.12/share) versus $10.2M loss a year ago, with zero revenue. Key pipeline catalysts include Phase 1 dosing of OV4071 and advancement of OV329 into Phase 2 and new pediatric indications, supported by a $165.6M cash runway into 2029 after recent PIPE and warrant exercises.

Actionable Insight

Monitor upcoming Phase 2 data for OV329 in focal onset seizures (expected Q2 2026) and OV4071 proof-of-mechanism results from ketamine challenge study (H2 2026). Strong cash runway reduces near-term dilution risk, but no revenue means stock will move on clinical catalysts.

Key Facts

Q1 2026 net loss of $17.0M vs $10.2M in Q1 2025; EPS -$0.12 vs -$0.14
Revenue $0 vs $130K in prior year (no product sales)
Cash, equivalents and marketable securities $165.6M at March 31, 2026
Raised $60M gross in March 2026 PIPE; $53.9M from Series A warrant exercise
Advanced OV329: 9mg cohort cleared; Phase 2 in focal onset seizures expected Q2 2026
Initiated Phase 1 for OV4071 (KCC2 activator) in healthy volunteers in May 2026
Expanded OV329 development into tuberous sclerosis complex (TSC) and infantile spasms (IS)

Financial Impact

Net loss widened by 66% to $17M; cash position strengthened by $75M from capital raises

net losscash positionrevenue

Risk Factors

Clinical trial failure or safety issues with OV329 or OV4071
Dilution from future equity offerings despite current cash position
No approved products or revenue; cash burn rate increasing

Market Snapshot

Exchange

Nasdaq

Sector

Pharmaceutical Preparations

Analyst Consensus

94% bullish (17 analysts)

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

Document	Accession Number
PRESS-RELEASE Data (Synthetic)	press-3292680

9 reports for OVID

T+1T+5T+20T+60

Track record builds as more directional reports settle.

Filters

Reports for OVID — sortable, filterable
	Type				Now
Jun 3, 2026 11d ago	8-K NEUTRAL ★ 2/10	$2.39 $2.48	▲ +3.77%	▲ +3.37%	$2.30 (−3.77%)
May 12, 2026 4w ago	Press Release MIXED ★ 6/10	$2.87 $2.80	▼ −2.44%	▼ −3.01%	$2.30 (−19.86%)
Apr 27, 2026 7w ago	EFFECT NEUTRAL ★ 4/10	$2.69 $2.70	▲ +0.37%	▲ +0.86%	$2.30 (−14.50%)
Apr 21, 2026 7w ago	S-3 NEUTRAL ★ 4/10	$2.66 $2.68	▲ +0.75%	▲ +1.15%	$2.30 (−13.53%)
Apr 20, 2026 7w ago	8-K BULLISH ★ 6/10	$2.89 $2.85	▼ −1.38%	▼ −0.73%	$2.30 (−20.42%)
Mar 18, 2026 12w ago	8-K NEUTRAL ★ 4/10	$2.30 $2.30	· 0.00%	▲ +0.27%	$2.30 (−0.00%)
Mar 18, 2026 12w ago	Press Release MIXED ★ 6/10	$2.30 $2.30	· 0.00%	▲ +0.27%	$2.30 (−0.00%)
Mar 18, 2026 12w ago	Press Release NEUTRAL ★ 5/10	$2.30 $2.30	· 0.00%	▲ +0.27%	$2.30 (−0.00%)
Feb 23, 2026 16w ago	Insider Cluster NEUTRAL ★ 2/10	$1.45 $1.51	▲ +4.14%	▲ +3.40%	$2.30 (+58.62%)

US Market Status

Market Closed — Opens in 3h 16m

Related Tickers

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access